LY3372993 for Alzheimer's Disease

Recruiting in Palo Alto (17 mi)

+17 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Eli Lilly and Company

Trial Summary

What is the purpose of this trial?This trial is testing a new drug called LY3372993 to see if it is safe and how well people can tolerate it. The study includes people with Alzheimer's Disease and healthy individuals, both non-Japanese and first-generation Japanese. Researchers will measure how much of the drug gets into the bloodstream and observe its effects on the body.

Eligibility Criteria

This trial is for adults with Alzheimer's Disease (AD) showing memory decline for over 6 months and healthy individuals, including those of first-generation Japanese origin. AD participants need a partner to assist during the study. Healthy subjects must be within certain body weight limits and not on recent medications.

Inclusion Criteria

(Part A) Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to study visits or be available through telephone at designated times

If you want to take part in the study, you and your family must have Japanese heritage, and all your grandparents must have been born in Japan.

I am generally in good health.

+4 more

Exclusion Criteria

I have had serious dizziness or fainting episodes in the last 3 years.

(Part B) You have any important heart or brain scan irregularities.

I haven't taken any biologic drugs like monoclonal antibodies in the last 3 months or 5 half-lives, whichever is longer.

+8 more

Participant Groups

The safety and effects of LY3372993 are being tested in two parts: one with Alzheimer's patients and another with healthy people, possibly including first-generation Japanese individuals. The study will measure how much drug gets into the blood and its impact on participants.

4Treatment groups

Experimental Treatment

Placebo Group

Group I: LY3372993 (Part B)Experimental Treatment1 Intervention

LY3372993 administered as single dose IV or SC.

Group II: LY3372993 (Part A)Experimental Treatment1 Intervention

LY3372993 administered as multiple doses either intravenously (IV) or subcutaneously (SC).

Group III: Placebo (Part A)Placebo Group1 Intervention

Placebo administered as multiple doses IV or SC.

Group IV: Placebo (Part B)Placebo Group1 Intervention

Placebo administered as single dose IV or SC.